Use of recombinant factor VIIa (NovoSeven^®) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux

References

• Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, . Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:381S–453S.
   PubMed Web of Science ®Google Scholar
• Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk P, . Guidelines on the diagnosis and management of acute pulmonary embolism: The task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008;29:2276–315.
   PubMed Web of Science ®Google Scholar
• Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, . Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598–660.
   PubMed Web of Science ®Google Scholar
• Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001;345:1305–10.
   PubMed Web of Science ®Google Scholar
• Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, . Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695–702.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345: 1298–304.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, . Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464–76.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, . Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial. JAMA 2006;295:1519–30.
   PubMed Web of Science ®Google Scholar
• Blick SK, Orman JS, Wagstaff AJ, Scott LJ. Fondaparinux sodium: a review of its use in the management of acute coronary syndromes. Am J Cardiovasc Drugs 2008;8:113–25.
   PubMed Web of Science ®Google Scholar
• Fishman PE, Drumheller BC, Dubon ME, Slesinger TL. Recombinant activated factor VII use in the emergency department. Emerg Med J. 2008;25:625–30.
   PubMed Web of Science ®Google Scholar
• Levi M. Emergency reversal of antithrombotic treatment. Intern Emerg Med. 2009;4:137–45.
   PubMed Web of Science ®Google Scholar
• Ingerslev J, Vanek T, Culic S. Use of recombinant factor VIIa for emergency reversal of anticoagulation. J Postgrad Med. 2007;53: 17–22.
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Depasse F, Chakroun T, Samama MM, Elalamy I. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost. 2004;91:531–7.
   PubMed Web of Science ®Google Scholar
• Lisman T, Bijsterveld NR, Adelmeijer J, Meijers JC, Levi M, Nieuwenhuis HK, . Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost. 2003;1:2368–73.
   PubMed Web of Science ®Google Scholar
• Young G, Yonekawa KE, Nakagawa PA, Blain RC, Lovejoy AE, Nugent DJ. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis 2007;18:547–53.
   PubMed Web of Science ®Google Scholar
• Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, . Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002;106:2550–4.
   PubMed Web of Science ®Google Scholar
• Gatt A, van Veen JJ, Woolley AM, Kitchen S, Cooper P, Makris M. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost. 2008;100:350–5.
   PubMed Web of Science ®Google Scholar
• Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, . The calibrated automated thrombogram (CAT): A universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002;32:249–53.
   PubMed Web of Science ®Google Scholar
• Levi M, Bijsterveld NR, Keller TT. Recombinant factor VIIa as an antidote for anticoagulant treatment. Semin Hematol. 2004;41 (Suppl. 1):65–9.
   PubMed Web of Science ®Google Scholar
• Huvers F, Slappendel R, Benraad B, van Hellemondt G, van Kraaij M. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. Neth J Med. 2005;63:184–6.
   PubMed Web of Science ®Google Scholar
• Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, . Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: The CRUSADE (can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines) bleeding score. Circulation 2009;119:1873–82.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Atar D. Assessment of bleeding events in clinical trials—proposal of a new classification. Am J Cardiol. 2007; 99:288–90.
   PubMed Web of Science ®Google Scholar
• Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363:1791–800.
   PubMed Web of Science ®Google Scholar
• Hoffman M, Monroe DM, 3rd, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: Thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998;9:S61–5.
   PubMed Web of Science ®Google Scholar
• Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542–7.
   PubMed Web of Science ®Google Scholar
• Heuer L, Blumenberg D. Recombinant factor VIIa (NovoSeven). A review of current and possible future indications. Anaesthesist 2002;51:388–99.
   PubMed Web of Science ®Google Scholar